

Special Issue

Next-Generation Cancer Immunotherapy

Message from the Guest Editor

Cancer immunotherapy has become the standard in many advanced cancers. Recently, it has been applied to neoadjuvant and adjuvant settings in surgically resectable early cancers. In addition, various combinations and modalities are being developed in pre-clinical and clinical studies. This Special Issue focuses on the rationale and strategy of next-generation cancer immunotherapy based on basic and clinical immunology, especially modulation of the tumor microenvironment, antigen-specific immunotherapy, and biomarkers for precision medicine.

Guest Editor

Prof. Dr. Toshihiko Torigoe

Department of Pathology, Sapporo Medical University School of Medicine, S-1, W-17, Chuo-ku, Sapporo 060-8556, Japan

Deadline for manuscript submissions

closed (28 February 2025)



Immuno

an Open Access Journal
by MDPI

Impact Factor 2.5
CiteScore 3.7



mdpi.com/si/198635

Immuno
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
immuno@mdpi.com

[mdpi.com/journal/
immuno](https://mdpi.com/journal/immuno)





Immuno

an Open Access Journal
by MDPI

Impact Factor 2.5
CiteScore 3.7



[mdpi.com/journal/
immuno](https://mdpi.com/journal/immuno)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Toshihiko Torigoe

Department of Pathology, Sapporo Medical University School of
Medicine, S-1, W-17, Chuo-ku, Sapporo 060-8556, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO,
and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 31.6 days after
submission; acceptance to publication is undertaken in 2.9
days (median values for papers published in this journal in
the first half of 2025).